CF
ORIC icon

Cantor Fitzgerald’s Oric Pharmaceuticals ORIC Stock Holding History

Cantor Fitzgerald’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200,000
Closed -$1.12M – 509
2025
Q1 		$1.12M Buy
200,000
+177,296
+781% +$1.55M 0.02% 110
2024
Q4 		$183K Buy
+22,704
New +$208K ﹤0.01% 192

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Cantor Fitzgerald's ORIC Position: Q2 2025 in Review

Cantor Fitzgerald sold out of Oric Pharmaceuticals (ORIC) in Q2 2025, closing a stake of 200,000 shares — an estimated $1.12M sold.

Cantor Fitzgerald first reported a position in ORIC in Q4 2024 and held it in 2 quarters. The position peaked at $1.12M in Q1 2025. 142 funds tracked by Wall St. Rank hold ORIC as of Q2 2025.

  • Cantor Fitzgerald reported no remaining Oric Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 200,000 Oric Pharmaceuticals shares in Q2 2025, an estimated $1.12M.
  • Cantor Fitzgerald first reported a position in Oric Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Cantor Fitzgerald's Oric Pharmaceuticals position peaked at $1.12M in Q1 2025.
  • 142 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2025.

Based on Cantor Fitzgerald's 13F filing for Q2 2025, filed 14 Aug 2025.